375.jpg)
Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name 'Covihalt' for the treatment of patients with mild to moderate COVID-19 symptoms at ₹49 per tablet in India. Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.
Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name 'Covihalt' for the treatment of patients with mild to moderate COVID-19 symptoms at ₹49 per tablet in India. Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.
417.jpeg)
10.jpeg)
40.jpeg)
100.jpeg)
416.jpeg)
5.jpeg)
4.jpeg)
6.jpeg)
5.jpeg)
